Slideshow

Antipsychotic Augmentation vs Monotherapy in Schizophrenia

Author(s):

Brian Miller, MD, PhD, MPH

To augment or not to augment? That is the question.

View the slides in PDF format. Also see: Antipsychotics and Breast Cancer Risk.

Related Videos
schizophrenia
sc
schizophrenia
clozapine
brain
cognition
clock
clozapine
steering wheel
schizophrenia
Related Content
Parkinson disease
April 25th 2025

Depression, Apathy, and Anxiety in Parkinson Disease

Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP
Here's to a Psychedelic Revolution
April 9th 2022

Here's to a Psychedelic Revolution

Amir Inamdar MBBS, DNB (Psych), MFPM
schizophrenia
April 22nd 2025

Cobenfy as Add-On Treatment for Schizophrenia Fails to Meet Primary Endpoint in Phase 3 ARISE Trial

Leah Kuntz
Blue Light Blockers: A Behavior Therapy for Mania
October 7th 2021

Blue Light Blockers: A Behavior Therapy for Mania

Chris Aiken, MD Kellie Newsome, PMH-NP
clinical trial
April 21st 2025

MindMed Begins Phase 3 Emerge Study of MM120 in Patients With Major Depressive Disorder

Grace Koennecke
benzodiazepine
April 16th 2025

Benzodiazepine Discontinuation Associated With Increased Mortality in Patients on Stable, Long-Term Benzodiazepines

Geena Sutherland, MD Nancy Kartiko, MD Haley Schuster, MD Mark Mullen, MD Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP
© 2025 MJH Life Sciences

All rights reserved.